Malignant Male Reproductive System Neoplasm

subtype

Identifier: CI-CAN-00003180
Entity page: /cancer/malignant-male-reproductive-system-neoplasm ↗
Edges: 6,712

Neighbours: 15 genes20 drugs10 trials
Drawn: 45 of 45 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Male Reproductive System Neoplasm approved for …APPROVED_FORderived15 of 81show all (up to 200)
← approved for	Etoposidesmall molecule FDA (US) · approved · 2026-02-13 · Refractory testicular cancer	—	approved	Malignant Testicular Neoplasm	1	Regulatory	openfda	graph →
← approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

ATM Mutation OlaparibFDA US 2017-08-1717 active / 40 trials
Curatedlevel Asensitivity· support 2civicObservedATM altered in 4.2% (86 / 2,069 cases, largest of 8 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Malignant Prostate Neoplasm, Castration-Resistant Prostate Carcinoma
BRCA2 Mutation OlaparibFDA US 2017-08-1717 active / 40 trials
Curatedlevel Asensitivity· support 2civicObservedBRCA2 altered in 3.6% (74 / 2,069 cases, largest of 7 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Malignant Prostate Neoplasm, Castration-Resistant Prostate Carcinoma
BRCA1 Mutation OlaparibFDA US 2017-08-1717 active / 40 trials
Curatedlevel Asensitivity· support 2civicObservedcohort frequency not yet available for BRCA1 in this cancerRegulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Malignant Prostate Neoplasm, Castration-Resistant Prostate Carcinoma
CDK12 Mutation OlaparibFDA US 2017-08-1717 active / 40 trials
Curatedlevel Asensitivity· support 1civicObservedCDK12 altered in 5.7% (118 / 2,069 cases, largest of 7 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
CHEK2 mutation OlaparibFDA US 2017-08-1717 active / 40 trials
Curatedlevel Asensitivity· support 1civicObservedCHEK2 altered in 4.2% (21 / 499 cases)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
BRCA2 Mutation RucaparibFDA US 2016-12-192 active / 11 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA2 altered in 3.6% (74 / 2,069 cases, largest of 7 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinomacontext: Castration-Resistant Prostate Carcinoma
BARD1 Mutation OlaparibFDA US 2017-08-1717 active / 40 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BARD1 in this cancerRegulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
BRCA1 Mutation RucaparibFDA US 2016-12-192 active / 11 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BRCA1 in this cancerRegulatoryapproved for Castration-Resistant Prostate Carcinomacontext: Castration-Resistant Prostate Carcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Malignant Male Reproductive System Neoplasm altered in cohorts of …ALTERED_INderived15 of 144show all (up to 200)
← altered in cohorts of	CCAR2 298 / 500 cases (60 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	BIN3 297 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	C8orf58 297 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	XPO7 297 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	BMP1 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PEBP4 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PIWIL2 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PPP3CC 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	RHOBTB2 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	SORBS3 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TNFRSF10C 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	DMTN 295 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	DOK2 295 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	EGR3 295 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	FAM160B2 295 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →

Malignant Male Reproductive System Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 262show all (up to 200)
→ investigated in trials for	Docetaxelsmall molecule 236 trials (45 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	236	Observed	clinicaltrials	graph →
→ investigated in trials for	Enzalutamidesmall molecule 199 trials (70 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	199	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 193 trials (45 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	193	Observed	clinicaltrials	graph →
→ investigated in trials for	Leuprolideother 126 trials (30 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	126	Observed	clinicaltrials	graph →
→ investigated in trials for	Abiraterone Acetatesmall molecule 107 trials (39 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	107	Observed	clinicaltrials	graph →
→ investigated in trials for	Bicalutamidesmall molecule 106 trials (17 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	106	Observed	clinicaltrials	graph →
→ investigated in trials for	Goserelinother 95 trials (17 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	95	Observed	clinicaltrials	graph →
→ investigated in trials for	Degarelixother 86 trials (20 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	86	Observed	clinicaltrials	graph →
→ investigated in trials for	Abirateronesmall molecule 80 trials (32 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	80	Observed	clinicaltrials	graph →
→ investigated in trials for	Apalutamidesmall molecule 71 trials (33 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	71	Observed	clinicaltrials	graph →
→ investigated in trials for	Darolutamidesmall molecule 57 trials (40 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 51 trials (20 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	51	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 49 trials (20 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	49	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabazitaxelsmall molecule 48 trials (15 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	48	Observed	clinicaltrials	graph →
→ investigated in trials for	Flutamidesmall molecule 42 trials (5 active) · roll-up of the cancer and its descendants	—	—	Malignant Male Reproductive System Neoplasm	42	Observed	clinicaltrials	graph →

Malignant Male Reproductive System Neoplasm studied in …STUDIED_INderived10 of 6,225show all (up to 200)
→ studied in	NCT01230866Phase 3 · active not recruiting Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer · condition mapped CURATED_EXACT · 6,225 trials mapped (1,836 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01242072Phase 1 · completed Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies · condition mapped CURATED_EXACT · 6,225 trials mapped (1,836 active)	—	—	Malignant Testicular Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01492972Phase 3 · recruiting Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer · condition mapped CURATED_EXACT · 6,225 trials mapped (1,836 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 6,225 trials mapped (1,836 active)	—	—	Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped CURATED_BROADER · 6,225 trials mapped (1,836 active)	—	—	Penile Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05081193Phase 2 · active not recruiting Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer · condition mapped CURATED_EXACT · 6,225 trials mapped (1,836 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06011304Phase 3 · completed Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer · condition mapped CURATED_EXACT · 6,225 trials mapped (1,836 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06541210NA · recruiting Building Community Living Labs in Black Communities to Advance Prostate Health Equity and Reduce Prostate Cancer Disparities in Black Men · condition mapped ONTOLOGY_EXACT · 6,225 trials mapped (1,836 active)	—	—	Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06738303Phase 2 · recruiting Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer · condition mapped CURATED_BROADER · 6,225 trials mapped (1,836 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06906471Phase 1/Phase 2 · active not recruiting A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS · condition mapped CURATED_EXACT · 6,225 trials mapped (1,836 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →